anti-MDA5+ amyopathic dermatomyositis (ADM) with ILD is severe and refractory. NEJM letter reports on 18 ADM Rx w/ tofacitinibs who showed better 6 mo survival (100% vs 78%) (P=0.04) and improved ferritin, FVC, DLCO, & CT Chest over time. https://t.co/lsVGPxChoO